A randomized study to evaluate safety and efficacy of transitioning therapy from alendronate [alendronic acid] to denosumab (AMG 162) in postmenopausal women with low bone mineral density.

Trial Profile

A randomized study to evaluate safety and efficacy of transitioning therapy from alendronate [alendronic acid] to denosumab (AMG 162) in postmenopausal women with low bone mineral density.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Alendronic acid; Denosumab
  • Indications Bone resorption; Menopause; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms STAND
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 18 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top